Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs 985

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 985 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Pipeline programs

Page 2 of 21

  1. Anifrolumab

    AstraZeneca

    Cutaneous Lupus Erythematosus

    phase 3 other active

    1 trial

  2. Anifrolumab

    AstraZeneca

    Active Systemic Lupus Erythematosus

    phase 3 mab completed

    3 trials

  3. Anifrolumab

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 mab active

    1 trial

  4. Anifrolumab

    AstraZeneca

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  5. Anifrolumab

    AstraZeneca AB

    Moderate-to-severe Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  6. Apremilast 20mg

    Amgen

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  7. Asacol®

    Tillotts Pharma AG

    Active Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  8. Atacicept

    Vera Therapeutics

    Lupus Nephritis (LN)

    phase 3 small molecule terminated

    1 trial

  9. Azathioprine

    The First People's Hospital of Lianyungang

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  10. B007

    BRIGHT MINDS BIOSCIENCES INC.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  11. BI 695501

    Boehringer Ingelheim

    Arthritis, Rheumatoid

    phase 3 small molecule completed

    2 trials

  12. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  13. Baricitinib

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule terminated

    1 trial

  14. Baricitinib

    Eli Lilly and Company

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  15. Budesonide

    Bausch + Lomb Ireland Limited

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  16. Bupivacaine Liposome Injection

    United Therapeutics Europe Ltd

    Osteoarthritis

    phase 3 small molecule terminated

    1 trial

  17. C5041006

    Lacuna Pharma Pty Ltd

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  18. CA41705

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  19. CA42750

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  20. CEP-33457

    Teva Pharma GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    2 trials

  21. CF101

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  22. CF101 1 mg

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  23. CF101 2mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  24. CHS-0214

    Coherus Oncology

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  25. CHS-1420

    Coherus Oncology

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  26. CLNP023Q12301

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  27. CLOU064O12301

    Novartis Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  28. CLS2901C (human [allogeneic] chondrocyte sheets)

    CellSeed Europe Ltd

    Osteoarthritis of the Knee

    phase 3 mab active

    1 trial

  29. CNTO1275JPA3001

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  30. CNTO148UCO3003

    Janssen-Cilag Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  31. CNTO1959CRD3001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  32. CNTO1959CRD3004

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  33. CNTO1959CRD3005

    Janssen-Cilag International N.V.

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

  34. CNTO1959CRD3008

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  35. CNTO1959ISD3001

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  36. CNTO1959PBCRD3007

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  37. CNTO1959PSA3004

    Janssen-Cilag International N.V.

    Psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

  38. CNTO1959PSA3005

    Janssen-Cilag International N.V.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  39. CNTO1959PSO3012

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  40. CNTO1959PUC3001

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  41. CNTO1959UCO3001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  42. CNTO1959UCO3004

    Janssen-Cilag International N.V.

    Moderate to Severly Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  43. CONDROSULF 800 mg tabletta

    The George Institute

    Knee osteoarthritis with moderate to severe pain

    phase 3 small molecule active

    1 trial

  44. CP-690,550

    Pfizer

    Arthritis, Rheumatoid

    phase 3 small molecule completed

    3 trials

  45. CT-P13 3.11

    Celltrion Healthcare Australia Pty Ltd

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  46. CT-P55 3.1

    Celltrion Healthcare Australia Pty Ltd

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  47. CVAY736B2201

    Novartis Pharmaceuticals

    Autoimmune hepatitis

    phase 3 small molecule active

    1 trial

  48. CVAY736F12301

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

985 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.